Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.91B
Close$
$74.10
36.3% downside
Current Fair Value
36.3% downsideOvervalued by 36.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.91 Billion |
|---|---|
| Enterprise Value | $11.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.45 |
| Outstanding Shares | 105,377,000 |
Return
| Return on Equity | 7.73% |
|---|---|
| Return on Assets | 6.14% |
| Return on Invested Capital | 2.92% |
Valuation & Multiples
| P/E Ratio | 211.85 |
|---|---|
| PEG | 973.73 |
| Price to Sales | 16.61 |
| Price to Book Ratio | 19.38 |
| Enterprise Value to Revenue | 14.23 |
| Enterprise Value to EBIT | 550.29 |
| Enterprise Value to Net Income | 216 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$219.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.81
Average shareholder expectationRevenue Estimate
$323.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 26.63% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.25%▼ 79.01% |
|---|---|
| Total Invested | $30.04M▼ 99.59% |
| Investors Holding | 39▼ 412.00% |
ESG Score
No data
About Corcept Therapeutics Inc
730 employees
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...